premeeting intelligence for:

Steven H. Collis

,

Chairman, President & CEO at Cencora

Steven H. Collis

Chairman, President & CEO at Cencora
Decisive
Assertive
Fast-Paced
Determined
Persuasive
Ambitious
Dynamic
Visionary
Spontaneous
Pioneering
Adventurous
Casual
Enthusiastic
Personable
Adaptable
Optimistic
Inventive
Approachable
Warm
Hospitable
Intuitive
Friendly
Accommodating
Diplomatic
Composed
Thoughtful
Agreeable
Careful
Modest
Consistent
Conscientious
Perceptive
Calm
Diligent
Meticulous
Collected
Accurate
Rational
Reserved
Strong-willed
Skeptical
Straightforward
Efficient
Candid
Steadfast
Focused
Vigorous
Persistent
Location:
Greater Philadelphia, United States
Education:
University of the Witwatersrand - Bcom, Commerce and Bcomm (Honors)
Overview:
  • Spearheaded significant growth and innovation as President of the Specialty Group from 1994 to 2009
  • Successfully led as President and CEO of Cencora from 2011 to 2016
  • Currently serving as Chairman, President, and CEO of Cencora since 2016
Quotes

ON CENCORA'S ESG REPORT..

"We are immensely proud of the way our organization has continued to take action to benefit the environment and society" source

ON USE OF AI...

"There is a ton of potential and a lot of promise with AI, but we have to be thoughtful in our approach to adapt AI into our businesses and observe how it advances so we don’t get into a situation where it overtakes our goals and our purpose" source

ON ZERO TOLERANCE...

"The entire AmerisourceBergen leadership team, myself included, are committed to educating and addressing racism, and have zero tolerance for xenophobia and intolerance against the AAPI community and all diverse populations." source

DISC Type:
Captain (D)
DISC Type:
Driver (Di)
DISC Type:
Initiator (DI)
DISC Type:
Influencer (Id)
DISC Type:
Motivator (I)
DISC Type:
Encourager (Is)
DISC Type:
Harmonizer (IS)
DISC Type:
Counselor (Si)
DISC Type:
Supporter (S)
DISC Type:
Planner (Sc)
DISC Type:
Stabilizer (SC)
DISC Type:
Editor (Cs)
DISC Type:
Analyst (C)
DISC Type:
Skeptic (Cd)
DISC Type:
Questioner
DISC Type:
Architect (Dc)
How to communicate
Focus on their need for control and results, be direct and to the point.
Do
Provide specific details about the product's features and benefits
Highlight how the product will solve their problems and make their life easier
Don't
Beat around the bush or offer vague information
Be too pushy or salesy
When communicating with them, focus on being direct, confident, and results-oriented.
Do
Speak in a fast-paced, confident tone
Focus on the bottom line and how your product can help them achieve their goals
Don't
Use too much jargon or technical language
Waste time on small talk or irrelevant details
Focus on big ideas, big concepts, and fast action over analysis.
Do
Use a direct and assertive tone
Emphasize results and benefits over features
Don't
Use overly flowery language or too many details
Be pushy or aggressive
Communicate with energy and a lively approach. Engage them by communicating clearly and vividly.
Do
Use inspiring language and be enthusiastic
Show them how the product can enhance their social status or reputation
Don't
Be too technical or confusing
Focus solely on features without considering how it can improve their life
Communicate in a friendly, casual manner and highlight the benefits of the product. Avoid criticism or confrontation.
Do
Use a light-hearted approach to build rapport
Highlight how the product can benefit their life or work
Don't
Be overly critical or confrontational
Use overly technical or confusing language
Interact with them in a friendly, agreeable manner with a light-hearted approach. Avoid criticism and confrontation.
Do
Wrap your pitch with positivity and emotional language
Include personalized, warm greetings and sincere sign off
Don't
Use forceful or high-pressure language
Talk too much about past experience without explaining the important insights
Focus on building a personal relationship and finding common ground. Speak positively and offer reassurance about the product.
Do
Engage them in conversation and find out their interests and concerns
Offer personalized recommendations and highlight how the product can meet their needs
Don't
Push too hard or use aggressive sales tactics
Dismiss or minimize their concerns or objections
Provide detailed information and use a friendly, personal tone
Do
Explain how your product can meet their specific needs
Use stories or examples that they can relate to
Don't
Use technical language or jargon
Push for a quick decision without building rapport first
Provide a warm, friendly greeting and use positive, upbeat language. Focus on building a relationship and show acceptance for who they are.
Do
Use friendly, expressive language
Refer to common interests and associations
Don't
Use a serious, businesslike tone
Bring up your flaws before they do
Focus on building a relationship and connecting with them on a personal level.
Do
Use a warm, friendly tone
Ask about their interests and hobbies
Don't
Use overly technical language
Pressure them into making a decision
Be friendly and focus on building a relationship with them. Use a light-hearted approach and avoid criticism or confrontation.
Do
Focus on building a friendly relationship
Validate their opinions and approach with positive language
Don't
Use forceful or high-pressure language
Force an aggressive sales pitch
Use a straightforward and logical approach when communicating with them
Do
Provide data and logical reasoning to support your claims
Use clear and concise language
Don't
Use overly expressive or emotional language
Use lots of anecdotes or storytelling
Use a serious, businesslike tone and focus on details, data, and results.
Do
Focus on their toughest problems.
Send additional data to support your pitch
Don't
Bring up your flaws before they do
Be unrealistically optimistic
Focus on providing logical reasoning and factual information. Be patient and answer their questions with clear and concise responses.
Do
Provide data-driven reasons for your product
Answer their questions with a well-thought-out response
Don't
Use overly expressive language
Speak in an overly casual manner
Focus on concrete data, specifics, and logistics. Avoid fluffy language and hype.
Do
Provide clear data and statistics to support the product
Present a clear, logical argument for why the product is worth investing in
Don't
Spend too much time on abstract concepts or big ideas
Get sidetracked with small details or anecdotes
When communicating with them, focus on being clear, concise, and results-oriented.
Do
Provide clear and concise information about the product and its benefits
Focus on results and practical details
Don't
Use overly descriptive or flowery language
Waste time on social chatter or small talk
Executive priorities
  • Enhance partnerships with pharmaceutical manufacturers to optimize supply chain efficiency.
  • Drive innovation in healthcare solutions to meet evolving market needs.
  • Foster a culture of excellence and diversity within the organization.
  • Maintain focus on financial performance and shareholder value while advancing healthcare access and outcomes.
Media
Investing.com

Cencora CEO Steven Collis sells over $2.5 million in company stock

Cencora, Inc. (NYSE:COR) has reported that its Chairman, President, and CEO, Steven H. Collis, sold a total of 10,755 shares of the company's common stock on March 19, 2024.

The Business Journals

Cencora CEO Steven Collis to retire; company names successor

The global wholesale pharmaceutical company is getting just its third CEO since it was created through a $7 billion merger in 2001.

PennState

AmerisourceBergen CEO talks about supply chain challenges during Smeal eventSteven Collis has worked for the company for nearly 25 years.

Steven H. Collis, chairman of the board, president, and chief executive officer of AmerisourceBergen, spoke in front of a packed crowd in the Business Building's Struthers Auditorium on Friday, Oct. 26.

Personality traits
Risk-Tolerant
Risk-Averse
Trusting
Skeptical
Optimistic
Pragmatic
Deliberate
Fast-Paced
Matter-Of-Fact
Expressive
Autonomous
Collaborative
Supporting
Dominant
Risk-Tolerant
Risk-Averse
Trusting
Skeptical
Optimistic
Pragmatic
Deliberate
Fast-Paced
Matter-Of-Fact
Expressive
Autonomous
Collaborative
Supporting
Dominant
Risk-Tolerant
Risk-Averse
Trusting
Skeptical
Optimistic
Pragmatic
Deliberate
Fast-Paced
Matter-Of-Fact
Expressive
Autonomous
Collaborative
Supporting
Dominant
Risk-Tolerant
Risk-Averse
Trusting
Skeptical
Optimistic
Pragmatic
Deliberate
Fast-Paced
Matter-Of-Fact
Expressive
Autonomous
Collaborative
Supporting
Dominant
Risk-Tolerant
Risk-Averse
Trusting
Skeptical
Optimistic
Pragmatic
Deliberate
Fast-Paced
Matter-Of-Fact
Expressive
Autonomous
Collaborative
Supporting
Dominant
Risk-Tolerant
Risk-Averse
Trusting
Skeptical
Optimistic
Pragmatic
Deliberate
Fast-Paced
Matter-Of-Fact
Expressive
Autonomous
Collaborative
Supporting
Dominant
Risk-Tolerant
Risk-Averse
Trusting
Skeptical
Optimistic
Pragmatic
Deliberate
Fast-Paced
Matter-Of-Fact
Expressive
Autonomous
Collaborative
Supporting
Dominant
Risk-Tolerant
Risk-Averse
Trusting
Skeptical
Optimistic
Pragmatic
Deliberate
Fast-Paced
Matter-Of-Fact
Expressive
Autonomous
Collaborative
Supporting
Dominant
Risk-Tolerant
Risk-Averse
Trusting
Skeptical
Optimistic
Pragmatic
Deliberate
Fast-Paced
Matter-Of-Fact
Expressive
Autonomous
Collaborative
Supporting
Dominant
Risk-Tolerant
Risk-Averse
Trusting
Skeptical
Optimistic
Pragmatic
Deliberate
Fast-Paced
Matter-Of-Fact
Expressive
Autonomous
Collaborative
Supporting
Dominant
Risk-Tolerant
Risk-Averse
Trusting
Skeptical
Optimistic
Pragmatic
Deliberate
Fast-Paced
Matter-Of-Fact
Expressive
Autonomous
Collaborative
Supporting
Dominant
Risk-Tolerant
Risk-Averse
Trusting
Skeptical
Optimistic
Pragmatic
Deliberate
Fast-Paced
Matter-Of-Fact
Expressive
Autonomous
Collaborative
Supporting
Dominant
Risk-Tolerant
Risk-Averse
Trusting
Skeptical
Optimistic
Pragmatic
Deliberate
Fast-Paced
Matter-Of-Fact
Expressive
Autonomous
Collaborative
Supporting
Dominant
Risk-Tolerant
Risk-Averse
Trusting
Skeptical
Optimistic
Pragmatic
Deliberate
Fast-Paced
Matter-Of-Fact
Expressive
Autonomous
Collaborative
Supporting
Dominant
Risk-Tolerant
Risk-Averse
Trusting
Skeptical
Optimistic
Pragmatic
Deliberate
Fast-Paced
Matter-Of-Fact
Expressive
Autonomous
Collaborative
Supporting
Dominant
Build rapport
  • Ask what he wants from the call
  • Be concise and to the point
  • Greet him with a serious, firm tone
Gather information
  • Learn what his competition is doing
  • Get through the most important questions up front
  • Figure out what problem he wants to solve
Discuss budget
  • Explain how he can save more money in the future
  • Allow some room for him to negotiate
  • Focus on efficiency and cost-effectiveness
Drive action
  • Point out the challenges he will face
  • Focus on the advantages he will gain
  • Be transparent about what you want him to do
Negotiate
  • Articulate your personal and mutual goals clearly
  • End the discussion and revisit it later if he is being too firm
  • Expect strong push-back
Work together
  • Ask yes/no questions about the current status
  • Provide a deadline for when you need an answer
  • Prepare specific questions to ask
  • Resist the temptation to apologize for being assertive

Cencora

Cencora (formerly AmerisourceBergen) is a pharmaceutical sourcing and distribution company that connects healthcare providers with pharmaceutical manufacturers. It plays a vital role in ensuring access to medications worldwide.
Industry:
Pharmaceutical
Headquarters:
Greater Philadelphia, United States
Revenue:
$72.30B
Employees:
46,000

How to negotiate

Keep the discussion casual, but be prepared for candid pushback, at times.
Keep your demo concise and to the point
Keep your demo concise and to the point
Keep your demo concise and to the point
Company Milestones
  • 2001: AmerisourceBergen formed through the merger of AmeriSource Health and Bergen Brunswig.
  • 2013: Ranked 12th on the Fortune 500 list.
  • 2015: Acquired MWI Veterinary Supply, expanding into animal health distribution.
  • 2020: Partnered with Walgreens Boots Alliance to create a global pharmaceutical sourcing partnership.

Demo your product

Notice how he uses your product and let him have fun trial-and-erroring on his own.
Keep your demo concise and to the point
Keep your demo concise and to the point
Top Products
  • Pharmaceutical sourcing and distribution
  • Specialty pharmaceutical distribution
  • Pharmacy automation and technology solutions
  • Consulting and business services in healthcare sector
Key Executives
  • Steven H. Collis - Chairman, President, and Chief Executive Officer
  • Silvana Battaglia - Executive Vice President and Chief Human Resources Officer
  • Elizabeth Campbell - Executive Vice President and Chief Legal Officer
  • Gina K. Clark - Executive Vice President and Chief Communications and Administration Officer
  • Robert P. Mauch, PharmD, PhD - Executive Vice President and Chief Operating Officer
Company Stock Performance
Key News
The Wall Street Journal

AmerisourceBergen Shuttering Compounding Unit PharMEDium

AmerisourceBergen Corp. on Thursday said it is pulling the plug on its PharMEDium Healthcare Holdings Inc.

Jan, 2020

The Guardian

Big pharma executives mocked ‘pillbillies’ in emails, West Virginia opioid trial hears

The US courthouse in Charleston, West Virginia. The city of Huntington and surrounding Cabell county are suing AmerisourceBergen and two other major distributors.

May, 2021

Bloomberg

AmerisourceBergen Board Beats Opioid Lawsuit by Pension Funds

AmerisourceBergen Corp. board members escaped investor litigation over its role in the opioid epidemic.

Dec, 2022

Reuters

AmerisourceBergen sees upbeat annual profit on specialty pharma strength

Drug distributor AmerisourceBergen (ABC.N), opens new tab raised its full-year profit forecast on Wednesday.

Aug, 2023

Competitive Landscape
Annual Revenue:
$72.30B
  • Serving a vast network of over 265 million customers worldwide
  • Generated $72.3 billion in revenue in 2023
  • Leveraging digital platforms to expand reach, Cencora has facilitated access to healthcare products and information for millions online
  • Supporting the delivery of quality care and improving patient outcomes
Annual Revenue:
$12.30B
  • Serving a vast network of over 280 million customers globally, Henry Schein stands as a premier provider in the healthcare industry
  • Surpassing 120 million users on HenrySchein.com by 2024
  • Achieved $12.30 billion in revenue in 2023, underscoring Henry Schein's position as a leading player in the global healthcare market
Annual Revenue:
$80.89B
  • Achieved 306M+ users on Mckesson by 2023
  • $80.898B revenue in 2023, over 14.77% revenue growth year-over-year
  • McKesson offers integrated healthcare solutions for improved patient outcomes.
Annual Revenue:
$205.00B
  • Serves over 280 million customers, offering vital healthcare solutions and services to communities around the world
  • Achieved $205 billion in revenue in 2023
  • From pharmaceutical distribution to medical products and services, Cardinal Health caters to the varied needs of healthcare providers, institutions, and patients

Want help preparing for your next meeting?

Our zero-software service is designed to make you confident
and well-prepared before your most important meetings.